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DISSERTATION ABSTRACT 
 
Elaine deLorimier 
 
Doctor of Philosophy 
 
Department of Chemistry and Biochemistry 
 
June 2015 
 
Title: Structure-Stabilizing RNA Modifications Prevent MBNL Binding to Toxic CUG 
and CCUG Repeat RNA in Myotonic Dystrophy 
 
 
Myotonic dystrophy is a genetic neurodegenerative disease caused by repeat 
expansion mutations. Myotonic dystrophy type 1 (DM1) is caused by a CTG repeat 
expansion in the 3’ UTR of the dystrophia myotonia protein kinase (DMPK) gene, while 
myotonic dystrophy type 2 (DM2) is caused by a CCTG repeat expansion in intron 1 of 
the zinc finger protein nine (Znf9) gene. When expressed, these genes produce long 
CUG/CCUG repeat RNAs that bind and sequester a family of RNA-binding proteins 
known as muscleblind-like 1, 2 and 3 (MBNL1, MBNL2, MBNL3). Sequestration of 
these proteins plays a prominent role in pathogenicity in myotonic dystrophy. MBNL 
proteins regulate alternative splicing, and myotonic dystrophy symptoms are a result of 
mis-spliced transcripts that MBNL proteins regulate. MBNL proteins bind to a consensus 
sequence YGCY (Y = pyrimidine), which is found in CUG and CCUG repeats, and 
cellular RNA substrates that MBNL proteins bind and regulate. CUG and CCUG repeats 
can form A-form helices, however it is hypothesized that MBNL proteins bind to the 
helices when they are open and the YGCY binding site is single-stranded in nature. To 
evaluate this hypothesis, we used structure-stabilizing RNA modifications pseudouridine 
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(Ψ) and 2’-O-methylation to determine if stabilization of CUG and CCUG repeat helices 
affected MBNL1 binding and toxicity. We also used Ψ to determine if the structure-
stabilizing modification affected MBNL binding to single-stranded YGCY RNA. CUG 
repeats modified with Ψ or 2’-O-methyl groups exhibited enhanced structural stability 
and reduced affinity for MBNL1. Ψ also stabilized the structure of CCUG repeats and 
rigidified single-stranded YGCY RNA and inhibited MBNL1 binding to both of these 
RNAs. Binding data from CCUG repeats and single-stranded YGCY RNA suggest that 
both pyrimidines in the YGCY motif must be modified for significant inhibition. 
Molecular dynamics and X-ray crystallography suggest a potential water-bridging 
mechanism for Ψ-mediated CUG repeat stabilization. Molecular dynamics simulations 
suggest that Ψ increases base-stacking interactions, and reducing the flexibility of single-
stranded RNA leads to reduced MBNL1 binding. Ψ modification rescued mis-splicing in 
a cellular DM1 model and prevented CUG repeat toxicity in zebrafish embryos.  
     This dissertation includes previously published and unpublished coauthored material. 
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CHAPTER I 
 
INTRODUCTION 
 
Alternative splicing 
The human genome consists of roughly 20,000 genes, while the human proteome 
is comprised of millions of different proteins1,2. The central dogma of molecular biology 
states that genomic DNA is transcribed into messenger RNA (mRNA), which is then 
translated into protein. If the process were this simple, each gene would encode for only a 
single protein, which, due to the difference in genome size versus proteome size, cannot 
be the case. RNA that is transcribed directly off of genomic DNA is called pre-mRNA, 
and contains many sequence elements that do not encode the protein sequence. Sequence 
elements such as introns, and 5’ and 3’ untranslated regions are removed from pre-
mRNA, leaving mature mRNA that is made up of exons and other mRNA features. 
Diverse cellular mechanisms exist to modify pre-mRNA so that a number of different 
protein isoforms can be expressed off of a single gene. These include alternative pre-
mRNA splicing, post-transcriptional modifications and alternative polyadenylation sites2. 
Intronic sequences are noncoding elements of pre-mRNA, while exonic sequences 
encode protein sequences. The spliceosome is the complex molecular machine that 
removes introns and ligates exons together through transesterification reactions, one of 
the process that is required for mature mRNA production3. Most exons in any certain 
gene are constitutively included in mature mRNA, while some exons are only included in 
the mRNA in certain tissues or developmental environments. Certain exons are either 
included or excluded in mRNA, and this process is known as alternative splicing. 
Alternative splicing and occurs in more than 90% of human transcripts3,4. The 
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Drosophila Dscam gene can express over 30,000 potential isoforms, but this is an 
extreme example5. 
There are a number of different types of alternative splicing, including cassette 
exon inclusion or exclusion, alternative 5’ or 3’ splice sites, mutually exclusive exons and 
intron retention (Figure 1). Cassette exon alternative splicing, in which exons are either 
Figure 1: Types of alternative splicing. (A) A cassette exon event will either 
include or exclude a certain exon. (B) In the case of mutually exclusive exons, 
the inclusion of one exon prevents the inclusion of another. (C and D) The 
spliceosome can use alternative 5’ or 3’ splice sites to express different 
isoforms. (E) Sometimes intronic sequences are included in protein-coding 
mRNAs. 	  
Cassette Exons Mutually Exclusive Exons
Alternative 5’ Splice Sites Alternative 3’ Splice Sites
Intron Retention
Figure 1:
A B
C D
E
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simply included or excluded, is the most common form of alternative splicing6. During 
pre-mRNA processing, the spliceosome must choose which exons to include or exclude 
based on regulatory signals and splice-site strength. Cis-acting elements in the RNA itself 
influence splice-site choice. Some examples of these are the strength of the 5’ and 3’ 
splice sites, the polypyrimidine tract, and the branch point sequence. Certain cis-acting 
elements are considered enhancers or suppressors, which either encourage or discourage 
the spliceosome to choose a splice-site. Point mutations in any of these sequences can 
result in mis-splicing, producing transcripts that could express nonfunctional proteins, or 
be prematurely decayed7. Trans-acting elements are also critically important for 
appropriate splice-site choice, which can differ depending on tissue type or 
developmental phase. These trans-acting elements are regulatory molecules, including 
RNA-binding proteins and non-coding RNAs and they influence exon inclusion or 
exclusion8,9.  
Because alternative splicing is so highly regulated by proteins and non-coding 
RNAs, errors in this process can be detrimental to cellular function. Mis-spliced mRNA 
could result in biologically inactive proteins, or cause nonsense mediated decay due to 
introduction of premature stop codons. Therefore, depletion or disruption of certain 
isoforms due to mis-regulated alternative splicing is the basis for many diseases10. 
Diseases can result from errors in cis-factors, as well as depletion or disruption of trans-
acting splicing regulatory factors. Myotonic dystrophy is a disease that is largely 
attributed to disruption of proteins that regulate alternative splicing, resulting in the 
expression of mis-spliced isoforms11. 
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Myotonic dystrophy 
Myotonic dystrophy is a neurodegenerative disease that is the most common 
adult-onset form of muscular dystrophy. Myotonic dystrophy patients experience a wide 
variety of symptoms including cataracts, heart defects, insulin resistance, cognitive 
defects, muscle wasting, and myotonia. The namesake symptom of the disease, myotonia, 
is a condition in which muscles will contract, but have trouble relaxing. The disease is a 
genetic, autosomal dominant disorder that affects approximately 1 in 8000 people. There 
are two types of myotonic dystrophy. Myotonic dystrophy type one (DM1) is caused by a 
mutation that expands CTG repeats in the 3’ UTR of the dystrophia myotonica protein 
kinase (DMPK) gene. Unaffected individuals have 5-38 CTG repeats in this gene, while 
DM1 patients have up to thousands of CTG repeats12. Myotonic dystrophy type two 
(DM2) is caused by an expanded CCTG repeat mutation in intron one of the zinc finger 
protein nine (ZNF9) gene. DM2 patients can have very long expanded CCTG repeats 
(~75 to 11,000), however DM2 patients tend to have more mild symptoms than DM1 
patients. In both cases, the mutation is in a non-coding region of the affected gene, which 
results in the expression of long CUG or CCUG repeat RNAs in DM1 and DM2, 
respectively13.  When these long non-coding RNAs are expressed, they aggregate and 
form distinct nuclear foci, and RNA-binding proteins associate with these foci14.   
Long CUG and CCUG repeats contain an abundance of YGCY motifs (Y = 
pyrimidine), which is the binding site for a family of RNA-binding proteins that regulate 
alternative splicing15. The muscleblind family of proteins (MBNL1, MBNL2 and 
MBNL3) are RNA-binding proteins that regulate alternative splicing of hundreds of 
transcripts16,17. These proteins have been shown to bind to CUG and CCUG repeats and 
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are sequestered to the nuclear foci18-20. When sequestered to nuclear foci, MBNL proteins 
are no longer able to regulate alternative splicing, resulting in a number of mis-spliced 
transcripts expressed in myotonic dystrophy patients. Furthermore, a number of 
symptoms in DM1 and DM2 can be attributed to the expression of fetal isoforms in adult 
tissue11. MBNL proteins are expressed in adult tissues, and myotonic dystrophy is 
commonly an adult-onset disease, thus the lack of regulation of alternative splicing in 
myotonic dystrophy patients results in fetal splicing patterns. Some specific examples of 
symptom-causing fetal isoforms expressed in myotonic dystrophy patients are the 
chloride ion channel (Clcn1), cardiac troponin T (TNNT2), the insulin receptor (INSR) 
and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (Atp2a1). Myotonia can be caused 
by the lack of function of chloride ion channels in skeletal muscles, and MBNL proteins 
regulate alternative splicing of Clcn1. Patients with myotonic dystrophy have reduced 
levels of this protein in skeletal muscle, due to aberrant alternative splicing. Specifically, 
exon 7a of Clcn1 is excluded when MBNL proteins are present, and inclusion of exon 7a 
results in expression of a premature stop codon, which leads to nonsense-mediated decay 
(Figure 2A)21,22. Myotonic dystrophy patients can also have heart defects, caused by 
cardiac muscle dysfunction. Heart defects are the second most common cause of death in 
myotonic dystrophy patients23,24. MBNL proteins also regulate alternative splicing of 
TNNT2, and this transcript is mis-spliced in myotonic dystrophy patients’ cardiac 
muscles, resulting in the expression of the fetal isoform. The fetal isoform of TNNT2 
contains exon 5, while exon 5 is absent in the MBNL-regulated adult version (Figure 
2B)20,25. Another transcript that is found to be mis-spliced in myotonic dystrophy patients 
is INSR, which results in a resistance to insulin. When MBNL proteins are present, they 
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promote inclusion of INSR exon 11, which allows for expression of a functioning insulin 
receptor and healthy glucose metabolism (Figure 2C). The isoform lacking exon 11 has a 
MBNL
MBNL
MBNL
exon 6 exon 7a exon 7
exon 6 exon 7
exon 6 exon 7a exon 7
MBNL
exon 4 exon 6exon 5
exon 4 exon 5 exon 6
exon 4 exon 6
exon 10 exon 11 exon 12
exon 10 exon 12
exon 10 exon 11 exon 12
exon 23
exon 21 exon 22 exon 23
exon 21 exon 22
exon 21 exon 23
TNNT2 
pre-mRNA
adult
TNNT2 
fetal
TNNT2 
healthy cardiac 
muscle
dysfunctional 
cardiac muscle
INSR
pre-mRNA
adult
INSR 
fetal
INSR 
Clcn1
pre-mRNA 
fetal
Clcn1
adult
Clcn1
pre-mature stop 
codon,
nonsense mediated 
decay,
myotonia
functional Cl 
channels
insulin-binding 
receptor  
low signaling 
capacity, 
insulin resistance 
Atp2a1
pre-mRNA
adult
Atp2a1
fetal
Atp2a1
Figure 2:
A
Ca2+ buildup, 
muscle weakness
Ca2+ fluxuation,
healthy skeletal 
muscle
Figure 2: Examples of MBNL-regulated alternative splicing. (A) MBNL 
promotes exclusion of the Clcn1 exon 7a. Inclusion of exon 7a results in a 
premature stop codon and nonsense mediated decay. (B) MBNL promotes 
exclusion of the TNNT2 exon 5. Inclusion of exon 5 leads to cardiac muscle 
defects. (C) MBNL promotes inclusion of the INSR exon 11. Exclusion of exon 
11 leads to insulin resistance. (D) MBNL promotes inclusion of the Atp2a1 exon 
22. Exclusion of exon 22 leads to Ca2+ buildup in skeletal muscle and muscle 
weakness. 
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lower signaling capacity, and an increase in expression of the receptor leads to insulin 
resistance12,26,27. Myotonic dystrophy patients also express higher levels of the fetal 
isoform of Atp2a1, which codes for a protein that regualtes Ca2+ fluxuation in adult 
muscle. MBNL proteins promote inclusion of exon 22, which is the isoform that is 
present at decreased levels in myotonic dystrophy patients (Figure 2D). Increased Ca2+ 
levels and muscle weakness in myotonic dystrophy patients has been attributed to this 
mis-splicing event28,29. All of these MBNL-regulated transcripts contain its consensus 
binding sequence (YGCY) and MBNL binds directly to them15,30. However, when 
MBNL proteins are bound and sequestered to CUG and CCUG repeats, they are unable 
to access their target transcripts and mis-regulation of the transcripts leads to myotonic 
dystrophy symptoms. It is therefore important to understand exactly how MBNL proteins 
interact with their YGCY binding site, in order to develop therapeutic strategies that 
would prevent MBNL binding to CUG and CCUG repeats.  
RNA structure and MBNL1 interaction 
 Efforts to understand the molecular basis for myotonic dystrophy began shortly 
after CUG repeats and CCUG repeats were identified as the toxic molecules myotonic 
dystrophy patients. Specifically, studies were planned to determine the structure of CUG 
repeats in order to understand how they function as toxic molecules and provide a basis 
for structure-based drug design. An initial study used chemical and enzymatic probing to 
determine that CUG repeats form “slippery” hairpins31. This finding was further validated 
with NMR and crystal structures, establishing that CUG repeats form A-form helices 
with G-C base pairs and U-U mismatch base pairs (Figure 3A, C)32,33. The crystal 
structure of CUG repeats indicated that the U-U mismatches do not distort the backbone, 
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as other structures have been shown to do34. 
By comparing the conformation of U-U 
mismatches from a number of structures, it 
was determined that the U-U mismatches in 
CUG repeat helices are rather dynamic33. 
Because of the number of different possible 
U-U mismatches that form in CUG repeats, 
there is no established conformation of the U-
U mismatch. A later study also found that 
CCUG repeats form A-form helices (Figure 
3B)35. With the knowledge that CUG and 
CCUG repeats are helical, a model was 
developed in which MBNL associates with 
CUG and CCUG repeats by interacting with 
the major or minor groove of helical RNA. 
However, efforts to co-crystallize MBNL1 
with CUG repeats in order to determine 
MBNL1’s mode of binding to CUG repeats were unsuccessful, possibly due to 
unstructured regions of the protein.  
MBNL proteins contain four highly conserved zinc finger domains that fold into 
two distinct and similar motifs (ZnF1/2 and ZnF3/4)36,37. Teplova et al in 2008 co-
crystallized the isolated ZnF3/4 with a short YGCY-containing RNA (CGCUGU). This 
structure refuted the previous hypotheses that MBNL proteins bind the outer faces of 
Figure 3:
A B CUG repeat helix
U-U mismatches
CCUG repeat helix
C 
Figure 3: Structures of CUG and 
CCUG repeats and examples of U-U 
mismatches. (A) Crystal structure of 
CUG repeats in an A-form helix. (B) 
Crystal structure of CCUG repeats in 
an A-form helix. (C) Two examples 
of the conformations of U-U 
mismatch base pairs found in 
different crystal structures.  	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CUG and CCUG repeat helices. The RNA associated with ZnF3/4 makes contacts with 
the protein via the Watson-Crick face of the GC dinucleotide (Figure 4)38. In helical CUG 
and CCUG repeats, the Watson-Crick face of the GC dinucleotide forms base pairs with 
the opposing strand, rendering it unable to interact with MBNL proteins. This discovery 
led to the development of a new hypothesis on how MBNL interacts with CUG and 
CCUG repeats. It is proposed that mismatch base pairs destabilize the helices, and they 
exist in equilibrium between helical RNA and an open, single-stranded state. 
Furthermore, we propose that when CUG and CCUG repeats are open and single-
stranded, MBNL proteins bind to the accessible Watson-Crick face of their YGCY 
binding sites. Following this model, stabilization of CUG and CCUG repeat helices 
should prevent MBNL binding to the toxic 
RNA and allow it to function normally, 
relieving myotonic dystrophy symptoms.  
RNA modification 
 Post-transcriptional RNA 
modifications are commonly employed in 
cells to alter the structure and function of 
RNA. Like alternative splicing and other post-
transcriptional RNA processing events, RNA 
modifications can also function as regulatory 
elements39. There are more than 90 different 
types of RNA modifications that have various 
functions. These functions include stabilizing 
Figure 4: Structure of a zinc finger of 
MBNL interacting with YGCY RNA. 
(A) A depiction of MBNL1’s ZnF3/4 
interacting with YGCY RNA. The 
protein is shown as a purple cartoon, 
RNA is shown as sticks and zinc 
atoms are shown as black spheres. 
(B) The sequence of the RNA that co-
crystallized with the zinc finger in 
this study.  	  
A
B 5’ C G C U G U 3’
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secondary structure, acting as sensors for a cell’s metabolic state, increasing translation 
efficiency and participating in other cellular processes40,41. A common and well-
established function of RNA modifications is to stabilize the structure of non-coding 
functional RNAs such as tRNA, rRNA, snRNA and RNA components of the 
spliceosome41. Pseudouridine (Ψ) and 2’-O-methylation are common RNA modifications 
found in the RNAs mentioned above. Ψ is an isomerization product of uridine, with a C-
C bond connecting the ribose to the base, and an extra N-H group at nucleoside position 
three (Figure 6A). Ψ modification in tRNA, rRNA and spliceosomal RNA is position-
specific and highly conserved, suggesting an important functional role for this 
modification42. 2’-O-methylation is similarly conserved and has been shown to affect 
RNA folding to promote hairpin formation rather than duplexing, implying it is important 
for structural integrity43. 2’-O-methylation of the U2 snRNA is fundamental for 
spliceosome assembly44. 2’-O-methylation is also commonly found in small RNAs in 
order to protect against 3’ to 5’ degradation 45. Both modifications have been shown to 
increase the thermal stability of RNA via different mechanisms46-48. Ψ, with its extra N-H 
group, has the capability of forming unique hydrogen bonds with neighboring atoms and 
it has been shown to form water bridges to induce stability46. Other studies have 
attributed an increase in structural stability with Ψ modifications to enhanced base-
stacking interactions with neighboring bases46,49. 2’-O-methyl modifications appear to 
induce structural stability by pushing the ribose to maintain a 3’endo conformation. 
Specifically, the methyl group induces C3’endo conformation through steric repulsion 
between the 2-carbonyl group and the 2’ methoxy group48.  
 Based on the model for CUG and CCUG repeat toxicity, we envisioned that if 
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structure-stabilizing modifications are incorporated in these repeats, MBNL proteins will 
be less likely to bind to them and become sequestered. In chapters II and III, I address the 
structural effects Ψ and 2’-O-methylation have on CUG repeats, CCUG repeats and 
single-stranded YGCY RNA, and MBNL’s ability to bind to modified RNA. Chapters II 
and III contain data that indicates that Ψ and 2’-O-methyl modifications do increase the 
structural stability of these RNAs and weaken MBNL1’s binding affinity in vitro. 
Chapter II provides evidence that MBNL is not sequestered to modified CUG repeats in 
vivo, and splicing patterns are normal in cells transfected with modified CUG repeats. In 
order to move forward with this information to a therapeutic strategy, we must address 
how modifications are carried out in vivo.  
 Pseudouridylation is carried out in vivo by an enzyme that catalyzes the breaking 
of the bond between N1 and the ribose, rotation of the base and formation of a bond 
between C5 and the ribose. This enzyme is part of pseuouridine-synthase, which is an 
enzyme-RNA complex designed for site-specific modification, called an H/ACA box 
RNP. The RNA in these complexes is small nucleolar RNA (snoRNA), and acts as a 
guide to target the specific site for modification. H/ACA box RNAs contain binding sites 
for pseudouridine synthases (Figure 5)50. 2’-O-methylation is carried out by C/D box 
RNPs, which have binding sites for methylases instead of pseudouridine-synthases51. 
H/ACA box and C/D box RNPs are otherwise quite similar. Both are composed of two 
interrupted stem-loops separated by a protein-binding site. Within the stem loops are 
single-stranded target recognition sequences that base pair with the RNA targeted for 
modification. During the modification process, the RNPs assemble around the targeted 
RNA, and the enzymes carry out the modification. Previous studies have shown that it is 
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possible to make designer H/ACA box and C/D box RNAs by modifying the target 
sequence such that it recognizes a different RNA, presumably one under 
investigation52,53. Thus, it is possible to envision that an H/ACA box or C/D box RNA 
designed to target CUG or CCUG repeats could be used as a therapeutic for myotonic 
dystrophy patients. RNAs introduced to patients would assemble with enzymes on the 
toxic repeats, which would then be modified. Modification would induce structural 
stability of the RNA, preventing MBNL binding, and allowing it to function normally.  
     This dissertation includes previously published and unpublished coauthored material. 
Figure 5: Schematic of H/ACA box snoRNP 
containing pseudouridine synthase. RNA targeted 
for pseudouridylation base-pair with targeting 
sequences in the stem loops of the snoRNA. 
Pseudouridine synthases bind to the H and ACA 
boxes and catalyze pseuouridylation of the target 
RNA.  	  
AGAAUAA ACA
Ψ synthase Ψ synthase
H-Box ACA-Box
H/ACA Box snoRNP
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CHAPTER II 
MODIFICATIONS TO TOXIC CUG RNAS INDUCE STRUCTURAL 
STABILITY, RESCUE MIS-SPLICING IN A MYOTONIC DYSTROPHY CELL 
MODEL AND REDUCE TOXICITY IN A MYOTONIC DYSTROPHY 
ZEBRAFISH MODEL 
 
 This work was published in Volume 42, Issue 18 of the journal Nucleic Acids 
Research in October 2014. I was the primary author on this manuscript. I performed the 
thermal melt assays, the binding assays, the in vitro transcription and the in vivo splicing 
assays. Dr. Leslie Coonrod and Emily Reister performed the crystallography. Jeremy 
Copperman performed the molecular dynamics simulations. Dr. Peter Todd and Kush 
Sharma performed the zebrafish viability and spontaneous coiling exeriments. Dr. J. 
Andrew Berglund was the principle investigator of this work.  
 
INTRODUCTION 
 Myotonic dystrophy is a genetic disorder that is the most common adult-onset 
form of muscular dystrophy, affecting ~1 in 8000 people. Myotonic dystrophy type one 
(DM1) is caused by a CTG repeat expansion mutation in the 3’ non-coding region of the 
dystrophia myotonica protein kinase (DMPK) gene. Unaffected individuals have up to 40 
CTG repeats at this location, while DM1 patients have >40 and up to thousands of CTG 
repeats29,54. Our current understanding of the DM1 disease mechanism is that the CTG 
repeats are transcribed into toxic CUG-repeat RNA, which sequesters RNA-binding 
proteins that are important for gene regulation12,37.  
 Muscleblind-like proteins (MBNL1, MBNL2 and MBNL3) are the primary RNA-
	   	   	  14 
binding proteins that are sequestered to the expanded CUG repeats18. MBNL proteins 
regulate alternative splicing and other RNA processing events55. During pre-mRNA 
splicing, the spliceosome must choose which exons to include based on developmental or 
environmental signals. This is a common regulatory event that vastly diversifies the 
proteome by allowing multiple protein isoforms to be expressed from a single gene. 
MBNL proteins function by interacting with their RNA binding sites within pre-mRNA 
downstream or upstream of alternatively spliced exons and direct the spliceosome to 
either include or exclude certain exons15,56. Many symptoms of DM1 are caused by 
expression of fetal isoforms due to mis-regulated alternative splicing11. For example, 
when MBNL genes are expressed in adults, they regulate the inclusion of the insulin 
receptor’s (INSR) exon 1127. One symptom of DM1 is insulin resistance that is likely 
partly due to the mis-regulation of this transcript11. Another MBNL target that is mis-
regulated in DM1 is cardiac troponin T (TNNT2). In this case MBNL promotes the 
exclusion of exon 557. Accordingly, one of the leading causes of death in DM1 is cardiac 
dysfunction, in part possibly due to mis-splicing of TNNT216,23.  
 MBNL proteins contain four Zn fingers that fold into two similar domains (each 
domain contains two Zn fingers) that bind RNA on opposing faces of the domain58,59. 
The consensus MBNL binding site is YGCY (Y represents pyrimidines), which is found 
in its pre-mRNA targets, and several copies of this motif are usually necessary for 
splicing regulation by MBNL proteins15,20. The CUG repeats are toxic because they 
contain hundreds or thousands of YGCY motifs repeated in the expanded CUG repeats60. 
Presumably, the many MBNL proteins binding the expanded CUG repeats leads to 
formation of aggregated MBNL-CUG repeat foci in patient cells and model systems61,62.  
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 Structure-probing, crystal and NMR structures have shown that CUG repeats can 
form double stranded A-form helices31-33,63,64. A crystal structure by Teplova and 
colleagues showed how a single MBNL1 zinc finger domain interacts with an RNA 
containing a YGCY binding site primarily via the Watson-Crick face of the nucletoides38. 
This result suggested that MBNL proteins will not bind or bind weakly to CUG repeats 
when they are in double-stranded or helical conformation, as the Watson-Crick faces of 
the bases form hydrogen bonds with the opposite strand, leaving them unavailable for 
interaction with MBNL. The resulting prediction is that if CUG repeats are stabilized in a 
double-stranded or helical structure, these repeats will have reduced or no toxicity 
because MBNL proteins will not be sequestered.  
 Structure-stabilizing modifications are commonly found in RNAs such as tRNA, 
rRNA and spliceosomal snRNAs42,65,66. Pseudouridine (Ψ) is an isomerization product of 
uridine and is the most common RNA modification (Figure 6A). It is known to play 
many important roles in many cellular processes42. Ψ has been shown to stabilize RNA 
structural components via base-stacking interactions and water-bridging interactions49,67. 
Another common RNA modification found in many cellular RNAs is the replacement of 
the hydrogen on the 2’-hydroxyl group with a methyl group and is known as 2’-O-
methylation (Figure 6B)45. Due to steric hindrance, 2’-O-methylation induces A-form 
helices in RNA and is also know to function as a stabilizing element in tRNA and 
rRNA48.  
Ψ and 2’-O-methyl modifications were introduced into CUG repeats to determine 
if these nucleotides stabilize the CUG repeats in a helical conformation. Both 
modifications do indeed increase the thermal stability of model CUG repeat RNAs and 
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reduce MBNL1’s affinity for model 
CUG repeats. A crystal structure of 
CUG repeats with a single Ψ 
substitution showed a water molecule 
bridging the Ψ-U non-canonical base 
pair. Molecular dynamics simulations 
support the model that this water bridge 
reduces the dynamic nature of the Ψ-U 
pair in helical CUG repeats. HeLa cells 
treated with in vitro-transcribed CUG 
repeat RNA caused mis-splicing of 
MBNL1 targets. 
Replacing uridine with Ψ in the 
CUG repeats rescued MBNL1-mediated 
splicing events. Furthermore, we found 
that incorporation of Ψ into a toxic CUG 
repeat RNA in a zebrafish model of 
DM1 ameliorated defects in motor 
function and enhanced viability.  
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Figure 6: Pseudouridine and 2’-O-methyl 
modifications increase the structural stability 
of (CUG)4 RNA. (A) Uridine and Ψ. Ψ an 
isomerization product of uridine. (B) 
Depictions of the structures of unmodified 
(CUG)4 RNA along with (CUG)4 with Ψ and 
2’-O-methyl modifications. (C) Melting curves 
for (CUG)4 RNAs modified with Ψ. The total 
change in melting temperature between 
unmodified (CUG)4 and 4Ψ(CUG)4 is ~20 °C. 
(D) Melting curves for (CUG)4 RNAs 
modified with 2’O methyl groups. The total 
change in melting temperature between 
unmodified (CUG)4 and 4-2’Ome(CUG)4 is 
 ~7 °C. 	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RESULTS 
Pseudouridine and 2’-O-methyl modifications increase the thermal stability of short 
(CUG)4 stem-loops  
 A thermal melting assay was used to determine if Ψ and 2’-O-methyl 
modifications stabilize a short, helical (CUG)4 RNA (Figure 6B). The modifications were 
targeted to the uridines because these were proposed as dynamic mismatches33. (CUG)4 
was synthesized with one, two and four Ψs in place of uridines (Figure 6B). Native 
(CUG)4 melted at 59 °C, while the analogs with one, two and four Ψs melted at 67, 72 
and 78 °C, respectively (Figure 6C, Table 1). (CUG)4 RNA containing one, two and four 
2’-O-methyl modification were studied as well (Figure 6B). The Tm increased to 62, 62 
and 66°C with one, two and four 2’-O-methyl modifications. These data indicate that Ψ 
has a more pronounced effect on stabilization of CUG repeats in comparison to 2’-O-
methylation.  
Table 1: Melting temperatures and MBNL1-affinities for (CUG)4 RNAs 
 
 
 
 
 
 
 
 
 
RNA Tm (°C) MBNL KD(µM) 
CUG4 59+/-1 0.30 +/- 0.1 
1ΨCUG4  67+/-2 1.0 +/- 0.3 
2ΨCUG4  72+/-1 6.0 +/- 2.0 
4ΨCUG4  78+/-1 >5 
1-2'OmeCUG4 62+/-2 0.65 +/- 0.2 
2-2'OmeCUG4 62+/-1 0.89 +/- 0.2 
4-2'OmeCUG4 66+/-1 1.0 +/- 0.2 
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MBNL1 has a reduced affinity for pseudouridylated and 2’-O-methylated (CUG)4 
The RNAs shown in figure 6B were used in gel-shift assays to determine how Ψ 
and 2’-O-methyl modifications affected MBNL1’s binding affinity for the (CUG)4 RNA. 
MBNL1 binds to (CUG)4 with a relatively strong affinity (Kd = 0.3 µM). The 
substitutions of one and two Ψs decreased MBNL1’s affinity for (CUG)4, resulting in Kds 
for these RNAs of 1.0  and 6.0 µM. Four Ψ replacements in (CUG)4 reduced MBNL1’s 
affinity to such an extent that the Kd was immeasurable in the assay used (Figure 7A, C, 
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Figure 7: Binding gels and curves for MBNL1-(CUG)4 RNA interactions. (A) 
Binding gels from MBNL1-(CUG)4 affinity assays for RNAs modified with Ψ. 
RNAs were radiolabelled with α-P32 and combined with different concentrations of a 
consensus MBNL1 sequence (amino acids 2-260). RNA-protein complex formation 
induces a band-shift due to an increase in size. KDs were calculated based on the 
signal from the radiolabeled RNA and values are approximately the [MBNL1] when 
50% of RNA is bound. (B) Binding gels from MBNL1-(CUG)4 affinity assays for 
RNAs modified with 2-’O-methylation. (C) Binding curves for (CUG)4 RNAs 
modified with Ψ. Data were fit to the following equation to determine KD values: 
fbound = fmax([MBNL1]/([MBNL1 + KD)). (D) Binding curves for (CUG)4 RNAs 
modified with 2’-O-methylation. KD values were calculated using the above 
equation. 
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Table 1).  
Modifying (CUG)4 with 2’-O-methylation also reduced MBNL1 binding such that 
1, 2 and 4 methyl modifications increased the Kd to 0.7, 0.9 and 1.0 µM, respectively 
(Figure 7B, D, Table 1). While 2’-O-methylation did decrease MBNL1’s affinity for 
CUG repeats, the effect was weaker than that of Ψ. These data are consistent with our 
model that increasing the stability of the double-stranded, helical conformation of the 
CUG repeats reduces or eliminates MBNL binding to CUG repeats in this conformation. 
A water molecule bridges the Ψ-U mismatch in a crystal structure and molecular 
dynamics simulations 
We previously utilized the GAAA tetraloop and its conserved 11 nucleotide 
receptor in order to facilitate the crystallization of CUG repeats (trCUG-3, Figure 8	  
A)33. In order to observe how Ψ affected the structure of CUG repeats, we substituted a Ψ 
in place of the U at position five in the trCUG-3 construct to create trCUG-3(Ψ5) (Figure 
8A). The trCUG-3(Ψ5) construct readily crystallized and the structure was successfully 
solved using the trCUG-3 structure for molecular replacement (see Table 2 for data 
collection and refinement statistics).  
Figure 8 (next page): A structure of CUG repeats with an incorporated 
pseudouridine and water occupancy through a molecular dynamics simulation. (A) 
Sequence and predicted secondary structure of constructs used in crystallography. 
CUG repeats (highlighted in blue) are attached to a GAAA tetraloop/receptor and 
the Ψ substitution is highlighted in red. trCUG-3 is the native structure and tr-CUG-
3(Ψ5) has the Ψ substitution. (B) Contacts made in the U5-U31 base pair and the 
Ψ5-U31 base pair. A bridging water coordinates the amine group of Ψ5 and the 
carbonyl group of U31. (C) Simulated annealing omit map (Fo − Fc) of Ψ-U pair 
and bridging water. (D) (CUG)5 RNA used in MD simulations. (E) Average degree 
of water occupancy throughout an MD simulation in U-U, Ψ-U and Ψ-Ψ base pairs. 
(F) Free energy required to open central base pairs.  	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This new structure of trCUG-3(Ψ5) at 1.90 angstroms resolution is nearly identical to the 
native trCUG-3 structure. Comparison of helical parameters of the CUG portion of  
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 Table 2: Summary of crystallography data collection and refinement statistics 
Measurement Value 
Space group R3 
Unit cell dimensions    a, b, c (Å) 69.70 69.70 67.80 
α, β, γ (°) 90 90 120 
Resolution range, Å 22.60 – 1.90 
Total number of reflections 46959 
Number of unique reflections 9697 
Average redundancy 5.0 
% completeness 96.9 (89.6) 
I/σI 22.7 (2.4) 
Rmerge a 0.051 (0.44) 
Average B-factors [no. of atoms]  
 nucleotides 52.32 [744] 
 solvent 55.783 [65] 
Rfree b 0.267 
Rwork b 0.196 
Values in parentheses represent highest resolution shell 
 
a  where I is the observed intensity and <I> is the average of intensities 
obtained from multiple observations of symmetry-related reflections. 
b  where Fo and Fc are the observed and calculated structure 
amplitudes, respectively. 
 
 
the lower helices showed two analogous, primary A-form helices (see Table 3 for helical 
parameters). However, there were key differences when the U5-U31 base pair from the 
native structure was compared to the Ψ5-U31 base pair (Figure 8B). Strikingly, there was 
a water molecule coordinating the amine group of Ψ5 to the carbonyl group of U31. 
Positions of the water and the non-canonical Ψ-U pair were confirmed by creating a 
simulated annealing omit map (Figure 8C). In order to form these two additional 
Rmerge =
I − I∑
I∑
Rfactor =
F0 − Fc∑
F0∑
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hydrogen bonds, the Ψ5-U31 base pair has a greater opening angle compared to U5-U31 
(Table 4) as well as a greater C1’-C1’ distance (Figure 8B). This bridging water adds two 
additional hydrogen bonds between uridine and Ψ and may contribute to Ψ’s structure-
stabilizing capabilities in the context of CUG repeats.  
 To assess the potential importance of this bridging water molecule in the Ψ-U 
base pair we used molecular dynamics (MD) simulations to study the structure of CUG 
repeats containing Ψ-substitutions. MD simulations allowed us to investigate how Ψ 
substitutions affected water coordination and stability of an internal U-U base pair in a 
simulated solution. The systems investigated in silico were hybridized (CUG)5 duplex 
RNA with zero, one, and two Ψ-substitutions at the middle (U8-U8) base pair (Figure 
8D). Simulations clearly displayed the presence of bridging water molecules, consistent 
with the crystal structure. RNA with Ψ is much more likely to adopt structures with 
bridging water molecules. It also showed how the likelihood for RNA of adopting 
secondary structures mediated by bridging water molecules increases with one and two Ψ 
substitutions. Bridging water molecules were counted by looking for any identifying 
solvent molecules that made contact with both pairing bases simultaneously. In a typical 
10 ns run of a MD simulation, the average degree of water coordination in a U-U 
mismatch throughout an MD simulation was 68.5% with respect to the water bridge. This 
value increased to 77.8% and 82.9% in Ψ-U and Ψ-Ψ mismatches, respectively (Figure 
8E).  
 We also used in silico approaches to study the energy required to break open U-U, 
Ψ-U and Ψ-Ψ base pairs in MD simulations. As expected, pseudouridylated base pairs 
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required more energy to open. The Ψ-Ψ required an additional 1.5 kcal/mol more energy 
to open compared to the U-U base pair (Figure 8F). Here we’ve shown that CUG repeats 
containing Ψ are not only able and likely to form a water bridge, the presence of the 
water appears to contribute to structural stability.  
Table 3: Comparison of CUG repeat helical parameters 
	  
	   	   	   	   	    B DNA1 A DNA1 (CUG)2 (CUG)2(Ψ5) 
Roll 0.6 8 9.17 10.09 
Twist 36 31.1 33.48 33.68 
Slide 0.23 -1.53 -1.34 -1.34 
Rise 3.32 3.31 3.1 3.17 
Inclination 2.1 14.7 18.57 20.05 
Helical twist 36.5 32.5 35.89 36.09 
x-displacement 0.05 -4.17 -4.7 -4.53 
Helical rise 3.29 2.83 2.39 2.44 
Zp -0.36 2.24 2.35 2.23 
Zp(h) -0.02 4.19 4.62 4.74 
 
Table 4: Comparison of U-U and Ψ-U non-canonical base pairs. 
 
	   	   	   	    trCUG-3   trCUG-3(Ψ5)   
  U2-U34 U5-U31 U2-U34 Ψ5-U31 
C1'-C1' 8.6 10.6 8.7 11 
1st hbond 2.8 2.7 2.8 2.7 
2nd hbond 2.8 - 2.9 - 
λ I 44.8 28.2 44.5 26.1 
λ II 75.9 55.8 73 53.1 
Incline1 minor minor minor minor 
Shear -2.47 -2.63 -2.26 -3 
Stretch -1.89 -1.33 -1.87 -1.17 
Stagger 0.26 -0.1 0.15 -0.34 
Buckle -7.12 5.62 -0.62 7.48 
Propeller -16.4 -7.12 -18.37 -6.69 
Opening 11.6 -25.98 10.22 -38.77 
Type Type I Type II Type I Type II 
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In vitro-transcribed CUG repeats disrupt MBNL-mediated alternative splicing and 
the effects are rescued by Ψ incorporation 
 After determining that Ψ substitutions stabilized the formation of secondary 
structure in the CUG repeat RNA and prevented MBNL1 binding, we next asked how 
pseudouridylation of CUG repeats would affect MBNL-mediated splicing events in a cell 
model. The significant effect on MBNL1 binding to CUG repeats suggested that 
pseudouridylated CUG repeats would not sequester MBNL proteins and the proteins 
would be free to regulate alternative splicing. To test this hypothesis, in vitro-transcribed 
CUG repeats with and without Ψ modifications were transiently transfected into HeLa 
cells along with MBNL-regulated splicing targets.  
 We used the T7 transcription system to generate (CUG)54 RNA with 0%, 50% and 
100% Ψ content. The T7 polymerase produced equivalent quantities of RNAs with UTP 
and ΨTP, suggesting that this enzyme efficiently incorporated the Ψ base. After cleanup, 
these RNAs were co-transfected into HeLa cells with two different mini-genes containing 
MBNL1-regulated exons. The TNNT2 and INSR mini-genes were used to monitor the 
effect of pseudouridylation on the ability of (CUG)54 RNA to alter splicing. A plasmid 
[DMPK(CTG)960] that had previously been shown to significantly alter MBNL-regulated 
splicing was used as a positive control15, as well as a plasmid [DMPK(CTG)40] with 
fewer repeats for comparison to the T7-produced (CUG)54 RNA.  
 The basal level of exon 5 inclusion for TNNT2 splicing reporter alone (mock) was 
50% due to the activity of endogenous MBNL proteins in the HeLa cells (Figure 9A,C). 
Transfecting the TNNT2 reporter as well as DMPK(CTG)40 and DMPK(CTG)960 resulted 
in 60% and 76% exon inclusion due to sequestration of MBNL proteins and a loss of 
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activity. MBNL proteins promote exclusion of exon 5 of TNNT215,57, so cellular 
expression of CUG repeats resulted in an increased level of exon inclusion as expected. 
Cells transfected with the in vitro-transcribed (CUG)54 with 0%, 50% and 100% Ψ 
altered the TNNT2 exon inclusion levels to 62%, 54% and 48%, respectively (Figure 
9A,C). The 62% level of exon 5 inclusion is comparable to 60% exon 5 inclusion 
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Figure 9: CUG repeats with increasing levels of pseudouridine are 
unable to induce mis-splicing of MBNL1-regulated targets TNNT2 
and INSR. (A) TNNT2 exon inclusion levels from a HeLa cell-
splicing assay. The difference in exon inclusion between the 0% Ψ 
samples and the 100% Ψ samples was statistically significant via a 
student’s t test with a p=0.0021. (B) INSR exon inclusion levels 
from a HeLa cell-splicing assay. p=0.0239. (C) A representative gel 
from the TNNT2 HeLa cell-splicing assay. Upper bands represent 
spliced transcripts with exons included and lower bands represent 
spliced transcripts with exons excluded. Quantification of these 
bands was used to obtain percent exon inclusion. (D) A 
representative gel from the INSR HeLa cell-splicing assay.  	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observed with the DMPK(CTG)40 plasmid, suggesting these two approaches resulted in 
similar levels of CUG repeats, and thus MBNL sequestration, in the cells. Ψ 
incorporation into (CUG)54 resulted in reversion to the basal level of exon inclusion 
(50%), presumably because MBNL proteins were no longer sequestered to the CΨG 
repeats and they were free to regulate TNNT2 exon 5 inclusion.  
 To determine if pseudouridylation was able to reduce or eliminate the change in 
splicing of another MBNL-mediated event, we measured exon inclusion levels of INSR. 
For this splicing event, MBNL1 promotes inclusion of the regulated exon, exon 1127. 
HeLa cells transfected with only the INSR reporter had an exon inclusion level of 67%, 
and co-transfection with DMPK(CTG)40 and DMPK(CTG)960 resulted in 43% and 46% 
exon 11 inclusion (Figure 9B,D). Transfection of (CUG)54 with 0% Ψ resulted in 58% 
exon 11 inclusion, an effect which is partially rescued by 50% Ψ (63% exon 11 
inclusion) and nearly fully rescued by 100% Ψ (66% exon 11 inclusion) (Figure 9B,D). 
These results are consistent with pseudouridylation of the CUG repeats reducing or 
eliminating the ability of the modified RNA to sequester MBNL proteins in this DM1 cell 
model.  
Pseudouridylated CUG repeats form reduced-sized foci 
Previous studies have show that extended CUG repeats form nuclear foci in DM1 
tissues, animal and cell culture models14. To determine whether pseudouridylated RNA is 
capable of forming RNA foci, we performed Fluorescence In-Situ Hybridization, probing 
for CUG repeats with a Cy-3 labeled (CAG)10 probe. HeLa cells were transfected with 
(CUG)54 RNA transcribed with 0%, 50% and 100% Ψ, as well as plasmids containing the 
DMPK 3’UTR with 40 and 960 CTG repeats as described above for the splicing assay. 
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Cells transfected with an unrelated plasmid (mock) formed 1.3 ± 0.6 foci/cell, while those 
transfected with DMPK(CTG)40 and DMPK(CTG)960 formed 21 ± 11 and 34± 12 
foci/cell, respectively. When we transfected cells with (CUG)54 RNA with 0%, 50% and 
100% Ψ they formed 19 ± 10, 15 ± 6 and 20 ± 7 foci/cell, respectively and there was no 
significant difference between unmodified and fully modified transfected RNA (Figure 
10, Table 5). However, cells transfected with fully modified CUG repeats tended to form 
smaller foci than those transfected with unmodified RNA. Large foci were deemed those 
with a volume larger than 0.2 µm3. The cells transfected with unmodified CUG repeats 
had 69 ± 17% large foci, while those transfected with fully modified CUG repeats had 47 
± 17% large foci. The difference in percent-large-foci between unmodified and modified 
RNA is significant with a p value less than 0.0001 (Figure 10, Table 5). 
Table 5: Quantification of CUG repeat foci 
 
   construct # foci  % lg foci (0.2 um^3) 
mock 1.3 ± 0.6 N=16 N/A 
DMPK:(CTG)40 21 ± 11 N=11 47 ± 17 N=11 
DMPK:(CTG)960 34 ± 12 N=12 41 ± 24 N=16 
(CUG)54 0% 19 ± 10 N=23 69 ± 17 N=27 
(CUG)54 50% 15 ± 6 N=20 68 ± 14 N=23 
(CUG)54 100% 20 ± 7 N=18 47 ± 17 N=31 
 
Figure 10 (next page): Pseudouridylated CUG repeats form reduced-size foci in 
HeLa cells. (A) Images of HeLa cells transfected with mock plasmid, plasmids 
containing 40 and 960 CTG repeats in the DMPK gene as controls, as well as 
cells transfected with (CUG)54  RNA with 0%, 50% and 100% Ψ . (B) Cells 
transfected with 960 CTG repeats tended to form more foci, while those 
transfected with 40 CTG repeats and modified and unmodified RNA formed 
similar numbers of foci. (C) Modified RNA did induce formation of foci that 
tended to be smaller than 0.2 µm3. 	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Pseudouridylation suppresses CUG repeat-associated toxicity in a zebrafish model 
of myotonic dystrophy 
To assess the in vivo effects of Ψ incorporation on CUG repeat-associated 
toxicity, we utilized an established zebrafish model of DM168. This model utilizes in 
vitro-transcribed RNA encoding GFP fused with the 3’UTR of DM1, which contains 91 
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CUG repeats. When injected into single cell embryos, this CUG RNA triggers alterations 
in morphology, viability, and motor behaviors within the first 24 hours of embryo 
development (Figure 11B,C)68. To assess the impact of pseudouridylation on CUG repeat 
toxicity in vivo, transcribed GFP-(CUG)91 RNAs with Ψ-NTP were injected into 
zebrafish embryos. We used GFP alone-encoding mRNA lacking CUG expansions with 
uridine or Ψ as a control (Figure 11A). RNA levels post-injection were measured using 
Figure 11: Viability and motoric function of zebrafish embryos injected with 
CUG repeat RNA is modified by pseudouridylation. (A) DMPK and GFP 
control constructs injected into zebrafish. (B) Viability of zebrafish embryos at 
24 hours post fertilization after injection with in vitro-transcribed GFP or 
GFP:(CUG)91 There was no significant difference in the viability of embryos 
injected with GFP with and without Ψ. N>400/>500 zebrafish per genotype 
over at least three independent experiments. For GFP vs (CUG)91 the p value 
was 0.014. For RNA (Ψ(CUG)91 vs (CUG)91 the p value was 0.030. P<0.05 by 
Fishers exact test. (C) Spontaneous coiling movements in 24 hpf zebrafish 
embryos injected with the indicated in vitro-transcribed RNAs. Ψ(CUG)91 
RNA vs GFP (p<0.0001). N>100/ zebrafish per genotype over 3 independent 
experiments were analyzed. All groups were significantly different by a 
Kruskal Wallis ANOVA. * indicates p<0.0001 by Post-hoc Mann-Whitney U 
test. 	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qRT-PCR to determine whether pseudouridylated RNA has a similar stability in the 
embryos and there was no significant difference between levels (Figure 12). As 
previously described68, injection of GFP-(CUG)91 mRNA into embryos led to a 
significant decrease in viability at 24 hours post-fertilization (hpf) compared to embryos 
injected with an equimolar amount of GFP RNA [GFP vs (CUG)91] (Figure 11B)68. In 
contrast, when embryos were injected with GFP-(CUG)91 RNA transcribed with 100% 
Ψ-NTP, survival at 24 hpf was significantly enhanced compared to 0% Ψ-NTP GFP-
(CUG)91 and was similar to embryos injected with GFP RNA (Figure 11B).  
 Zebrafish models of neuromuscular disorders often exhibit abnormalities in basic 
motor behaviors during early development 68,69. The first observable indication of skeletal 
muscle activity is spontaneous coiling, the alternating contraction of trunk and tail that 
begins at 17 hpf, peaks at 19 hpf and then decreases over the next 8 hours 70. At 24 hpf, 
zebrafish embryos injected with CUG repeats displayed a defect in spontaneous coiling 
Figure 12: CUG repeat levels in zebrafish are independent of modification. CUG 
repeat levels were measured in zebrafish embryos injected with unmodified and fully 
pseudouridylated (CUG)91 . The method used to measure RNA levels was qRT-PCR 
using primers specific for the injected transcript. Modified and unmodified levels of 
RNA were insignificantly different (p=0.61). 	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[GFP: 12 ± 0.52 coils/min, (CUG)91:10 ± 0.30 coils/min, p=0.022] (Figure 11C) 68. 
However, pseudouridylation of the CUG RNA completely abolished this toxicity, 
resulting in an increase in coiling activity [Ψ (CUG)91:15 ± 0.26 coils/min, p<0.0001] 
(Figure 11C). These results indicate that substituting Ψ for uridine in CUG repeats 
reduces the toxicity of the RNA as demonstrated by the rescue in viability and rescue 
(enhanced activity) of coiling activity.  
 
DISCUSSION 
 Structural and biochemical studies on MBNL1 with RNA substrates indicated that 
this family of proteins prefers to bind single-stranded or partially structured RNA38. This 
lead us to hypothesize that stabilizing the CUG repeats in a helical conformation with 
RNA modifications would decrease or eliminate MBNL binding to this toxic RNA. Of 
two RNA modifications tested, we found Ψ significantly stabilized the CUG repeats in a 
helical (A-form) conformation, and, as hypothesized, this stabilization of CUG repeats 
inhibited MBNL1 binding (Figures 6 and 7). Furthermore, in a DM1 cell model, 
pseudouridylation of CUG repeats reduced and eliminated the ability of the CUG repeats 
to cause mis-splicing of two MBNL1 splicing reporters (Figure 9). Significantly, 
pseudouridylation of a CUG repeat-containing mRNA protected zebrafish embryos from 
increased morbidity and decreased spontaneous coiling compared to mRNA without the 
Ψ modification (Figure 11). These studies are consistent with the model shown in figure 
13 that depicts pseudouridylation stabilizing CUG repeats in a helical conformation and 
not sequestering MBNL proteins (Figure 13C,D) while unmodified CUG repeats are less 
stable (or more prone to partial unfolding) and MBNL proteins are sequestered by the 
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repeats, and mis-splicing results (Figure 13A,B). While CUG repeats have been shown to 
form stable stem-loop structures via structure-probing assays, we have shown that Ψ 
induces further stabilization, preventing MBNL1 binding31. 
  Past efforts to understand the mechanism through which Ψ stabilizes RNA 
structure indicated that this modification leads to stronger base-stacking interactions with 
surrounding nucleotides and increased hydrogen bonding contacts through coordination 
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Figure 13: A model for CUG repeat detoxification via pseudouridylation. (A) CUG repeats 
form unstable helices that adopt multiple conformations, including partially unstructured 
RNA. MBNL1 binds to the CUG repeats and is sequestered to their location in the nucleus. 
MBNL1 is represented by green shapes. (B) When MBNL1 is sequestered to CUG repeats, 
it is unavailable to bind to the pre-mRNAs that it regulates. Here CUG repeats increased 
exon inclusion in the TNNT2 transcript. CUG repeats result in decreased exon inclusion in 
the INSR mRNA in the presence of CUG repeats. (C) CUG repeats with Ψ (CΨG repeats) 
form stable stem-loop structures. In these structures, MBNL1’s binding site is unavailable 
for interaction and MBNL1 is not sequestered. (D) MBNL1 is free to bind to its target 
transcripts when CΨG repeats are present. 	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with water molecules49. According to our analyses, the coordination of the water 
molecule induced formation of two extra H-bonds in the Ψ-U base pair compared to the 
U-U base pair (Figure 8B,C). Although this water in the crystal structure could be due to 
crystal packing, the MD studies with a CUG RNA containing Ψ showed a significant 
increase in the degree of water coordination in this same position compared to the 
unmodified CUG RNA (Figure 8D-F). It is likely that Ψ stabilizes RNA structure through 
different mechanisms and this new mechanism adds to the repertoire49.  
 Our results are consistent with CAG antisense and small molecule approaches that 
stabilize the CUG repeats in helical structures (no mismatches in CAG-CUG antisense 
interactions) or through binding of molecules to the CUG repeats in helical 
conformation71-73. However, CAG antisense and small molecule approaches do not 
address the secondary structure of RNA. Because modifying CUG repeats to stabilize 
structure prevents MBNL binding, we’ve shown that the secondary structure of the RNA 
is important in the DM1 disease mechanism. Furthermore, these data are congruent with 
approaches that stabilize CUG repeats in helical conformations and specific targeting of 
the U-U mismatches. SnoRNAs have been used to target RNAs with some promising 
results for altering RNA structure and function in cells52,53. To significantly 
pseudouridylate CUG repeats in vivo with snoRNAs would be quite challenging because 
of the abundance of sites and lack of specificity for specific uridines within the repeats, 
therefore this avenue is not currently being pursued.  
 More broadly, our results suggest that the conformation of toxic RNAs should be 
considered for disease mechanisms and therapeutic strategies. For example, the CCUG 
repeats that cause myotonic dystrophy type 2 can adopt multiple RNA structures 
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including possibly unfolded when protein-bound, partially unfolded, and two different 
helical structures with different mismatches20,35. The expanded CGG repeats in the 5’ 
UTR of the fragile X mental retardation 1 gene results in FTAXS, a disease characterized 
by ataxia, tremors, and neurodegeneration. Extended expansion of these repeats results in 
FXS, a common form of mental retardation74. RNA binding proteins associate with 
helical CGG repeats and are sequestered to nuclear inclusions63. Spinocerebellar ataxia 8 
(SCA8) is caused by expansion of CTG repeats in the ataxin 8 gene, and the resulting 
RNA gain of function produces cerebellar atrophy and coordination defects75,76. 
Expanded CUG repeats in SCA8 could exhibit the same pathogenic mechanism as that in 
DM1 and DM2, and RNA modifications could be used to help guide therapeutic 
strategies. SCA10 and ALS/FTD are autosomal dominant neurodegenerative diseases that 
are caused by expanded penta- and hexanucleotide repeats, and in both cases RNA-
binding proteins are sequestered to repeats, resulting in mis-regulation of splicing77-79. 
The RNA modification strategy described here is a powerful approach to address the 
conformation of RNA repeats associated with human diseases that should be considered 
for disease mechanism and therapeutic targeting.  
 
MATERIALS AND METHODS 
Thermal melts were carried out in 20 mM PIPES buffer at a pH of 7.0 and 150 
mM NaCl. The buffer was de-gassed before diluting RNA to a concentration of 2 µM. 
The temperature was raised by 1 °C per minute over a range of 25-95 °C, and absorbance 
at 260 nm was monitored by a Cary UV/Vis spectrophotometer. Absorbance was 
normalized by subtracting the absorbance at 25 °C. 
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GST-tagged MBNL1 (amino acids 2-260) was expressed in Arctic Express E. coli 
cells (Agilent TechnologiesTM) grown to an OD of 0.4, induced with 25 mM IPTG and 
shaken for 20 hours at 16 °C. GST-MBNL1 was initially purified over a Hi-TrapGST 
column on an FPLC. MBNL1 was then cleaved from GST by PreScission Protease and 
purified further by affinity chromatography over a Hi-TrapHeparin column. Both 
columns and the protease were made by GE Healthcare Life SciencesTM. MBNL1 
concentration was measured by a Bradford assay and the protein was stored in a buffer of 
500 mM NaCl, 50% glycerol, 25 mM Tris at pH of 7.5 and 5 mM BME at –80 °C until 
needed.  
RNA synthesized by Dharmacon was radiolabeled with α-32P phosphate with a 
polynucleotide kinase and stored at -20 °C in 20 mM Tris, pH 7.5. Prior to the binding 
reaction, CUG helices were diluted and folded by incubation at 95 °C in 20 mM Tris, pH 
7.5, 150 mM NaCl, and 5 mM MgCl2 for 2 min, followed by incubation on ice for 5 min. 
The RNA was then incubated with varying MBNL1 concentrations in 175 mM NaCl, 20 
mM Tris, pH 7.5, 1 mM BME, 10% glycerol, 5 mM MgCl2, 0.1 mg/mL heparin, 2 
mg/mL BSA, 0.02% xylene cyanol, and 0.05% bromophenol blue. The incubation was 20 
minutes at room temperature. RNA-protein complexes were separated from free RNA on 
a 6% native acrylamide gel. Complex formation was quantified by exposure on a 
phosphorimager screen followed by analysis with ImageQuant from GE Healthcare Life 
SciencesTM. Affinity constants were then calculated with the following equation: fbound = 
fmax([MBNL1]/([MBNL1+Kd)). The images of the gels were enhanced equally across 
each gel using Adobe Photoshop. No specific feature was enhanced. 
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The trCUG-3(Ψ5) construct was purchased from Dharmacon and deprotected per 
the manufacturer’s instructions. The RNA was then purified using HPLC and brought to 
a final concentration of 0.5 mM in a solution of 15 mM NaCl, 5 mM Tris (pH 7.5), and 5 
mM MgCl2. The RNA was annealed by heating to 70°C for 5 min and rapidly cooled to 
4°C. The best crystals grew from a mixture of 2 µL of RNA solution and 2 µL of well 
solution containing 4 mM MgSO4, 50 mM Tris (pH 8.5), and 30% (w/v) 1,6-hexanediol. 
Crystals appeared in approximately 1 week. 
Crystals were mounted in rayon loops and flash frozen in liquid nitrogen. 
Experimental data were collected at the Structural Biology Center at Argonne National 
Laboratory on the 19ID beamline under a cryostream. The X-ray data were integrated, 
merged, and scaled using the HKL-2000 program suite80 and converted to structure 
factors using the CCP4i GUI81 for the CCP4 program suite82. Data collection statistics are 
listed in Table 2. 
The structure was determined using molrep83, a part of the CCP4 program suite82, 
using the Protein Data Bank (PDB) entry 4FNJ, the structure of trCUG-3 33, as the search 
model. The model was rebuilt using Coot84 and refined with refmac85. Refinement 
statistics are listed in Table 2. Coot and PyMOL [Schrodinger, LLC (2010) The PyMOL 
Molecular Graphics System, Version 1.5.0.1.] were used to generate figures. Simulated 
annealing omit maps were created using CNS86 by deleting the Ψ5-U31 base pair as well 
as the coordinating water while all other nucleotides remained fixed during annealing. 
The structure was deposited in the PDB as entry 4PCJ. Structural parameters were 
computed using 3DNA87. 
Double-stranded (CUG)5 starting structures with 0, 1, and 2 Ψ modifications at 
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the central base pair were constructed from helical crystal structures of CUG repeats 
(PDB ID: 4FNJ). All simulations were performed utilizing the GROMACS88-91 molecular 
dynamics package on the ACISS cluster at the University of Oregon, using an AMBER92 
force-field optimized for stem-loop RNA structures with modified force-field parameters 
for the Ψ base93. All simulations were performed in explicit solvent utilizing the spc/e 
water model and 150 mM NaCl with excess sodium ions to neutralize the system, Ewald 
summation for the electrostatics, standard force-field cutoffs and parameters, and in the 
NVT ensemble. A 1 fs timestep was utilized, along with standard energy minimization 
and equilibration techniques, with over 5 nanoseconds of equilibration before collecting 
production data.  
 After equilibration, water-bridge occupancy was measured using the water-bridge 
collective variable of the PLUMED software package94. This collective variable is 
defined by a numerical function which assigns a continuous measure to the number of 
solvent atoms which are within 2 angstroms of an atom belonging to the A strand U8/Ψ8 
base and also within 2 angstroms of an atom belonging to the pairing B strand U8/ Ψ8 
base. This numerical function is rather lengthy and we refer the reader to the PLUMED 
documentation for further details. Statistics were collected over 10 ns of simulation. 
To obtain the free-energy in the center-of-mass base separation distance, first an 
approximate opening pathway was obtained by using the PLUMED94 implementation of 
Parrinello's metadynamics algorithm95 to jointly bias the number of base-pairing contacts 
and the center-of-mass base separation. Twenty images were chosen along this pathway, 
anchored using a harmonic restraining potential, from which umbrella sampling runs of 1 
ns each were performed. Final calculation of the free energy along the distance 
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coordinate was performed using the weighted historgram analysis method96 (Grosfield, 
Alan, "WHAM: the weighted histogram analysis method", version 
2.09, http://membrane.urmc.rochester.edu/content/wham). 
(CUG)54 was transcribed off of 300 ng of a linearized plasmid template containing 
a T7 promoter upstream of 54 CTG repeats. The reaction conditions were as follows: 0.1 
M DTT, 40 mM Tris, pH 8.0, 8 mM MgCl2, 50 mM NaCl, 2 mM spermidine 1 mM ATP, 
1 mM CTP, 1 mM GTP, 1 mM UTP/ΨTP, 1 µL RNasin (Ambion) and 1 µL T7 
polymerase in a final volume of 30 µL. Reactions were incubated at 37 °C for 2 hrs 
followed by addition of 3.3 uL of RQ1 DNase Buffer and 1 µL RQ1 DNase (Promega) 
and a 1 hr incubation at 37 °C. Transcribed RNA was purified by the addition of 80 µL of 
a 3.75 M LiCl, 25 mM EDTA solution and an overnight incubation at -20 °C. The RNA 
was then pelleted by centrifugation at 13,000 RPM and the liquid was removed. The 
pellets were washed in 1 mL of 70% ethanol, followed by re-pelleting and re-suspension 
in 30 µL of ddH2O. RNA concentrations were measured on a NanoDrop UV/vis 
spectrophotometer.  
 Reporter minigenes, DMPK(CTG)960, DMPK(CTG)40, and in vitro-transcribed 
RNA were transfected using Lipofectamine 2000 (Life Technologies). Control plasmids 
were added to transfections containing only reporter minigenes such that each set of cells 
received 1000 ng of nucleic acid. HeLa cells were routinely cultured as a monolayer in 
Dulbecco’s modified Eagle’s medium (DMEM)-GlutaMax medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Gibco) and 1x antibiotic/antimycotic at 37 
°C under 5% CO2. Prior to transfection, cells were plated in six-well plates at a density of 
2.0 x 106 cells per well. Cells were transfected 24 hrs later at approximately 90% 
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confluence using 500 µL of Opti-MEM (Life Technologies) and 5 µL of Lipofectamine 
2000. After 4 hours, Opti-MEM was replaced with DMEM. Cells were harvested in-plate 
after 24 hrs using the RLT buffer from QIAgen’s RNeasy kit.  
 Total RNA was isolated with the RNeasy kit per the manufacturer’s instructions. 
RNA samples were treated with RQ1 DNase and exon inclusion levels were analyzed by 
reverse transcription and PCR amplification as performed previously in this group97. 
Images of the gels were inverted and enhanced equally across each gel using Adobe 
Photoshop. No specific feature was enhanced. 
 Zebrafish experiments were conducted as described68. Briefly, embryos were 
isolated after paired mating of AB zebrafish (zFIN, Eugene, OR) and injected at the 1–2-
cell stage using a Drummond Nanoject. Diluted in vitro-transcribed capped and 
polyadenylated mRNA (4.6 nl each) was injected at a concentration of 100 ng/µL for all 
constructs unless otherwise specified (approximate total amount of RNA injected/embryo 
= 0.46 ng). Survival was determined by measuring the number of intact embryos after 
injection for each genotype and then determining the number of viable embryos at 24 hpf. 
For each injected RNA, as least 3 independent experiments were conducted, with at least 
two separate injection batches conducted per injected RNA at each experiment. The 
survival % was pooled across all studies and the 95% confidence interval was calculated 
using the method of Newcombe98. Fisher exact test was used to compare groups.  
Spontaneous coiling was measured as previously described69,99. Briefly, sets of 5 
embryos injected with the indicated RNAs were collected at 24 hpf and observed over 
four different 15-second periods. The number of coiling movements per minute per 
embryo was calculated. N>100/genotype from 3 independent experiments. A one-way 
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Kruskal Wallis ANOVA across genotypes was performed with post-hoc unpaired mann 
Whitney U tests conducted on pre-specified comparisons (GFP vs. CUG91 and CUG91 
vs. Ψ CUG91).  
Flourescence In-Situ Hybridization was carried out on HeLa cells transfected 
using the same procedure described above. Sixteen hours after transfection, cells were 
fixed in 4% paraformaldehyde for 15 minutes. Cells were then permeabilized with 0.5% 
triton X-100, in 1X PBS at RT for 5 min. Cells were prewashed with 30% formamide, 2X 
SSC for 10 min at RT. Cells were then probed overnight at 37 °C, with a 1 ng/µL of Cy3 
(CAG)10 probe (IDT, IA) in 30% formamide, 2X SSC, 2 µg/mL BSA, 66 µg/mL yeast 
tRNA, 2 mM vanadyl complex. Cells were then washed for 30 minutes in 30% 
formamide, 2X SSC at 42 °C, and then with 1X SSC for 30 min at RT. Cells were 
mounted onto glass slides using the hard-set mounting media that contains DAPI 
(Vectashield). Cells were imaged on an Olympus Fluoview FV1000 with a Bx61 scope. 
Unpaired, two-tailed t-tests were performed using Graphpad’s Prism 6. Images were 
prepared using ImageJ and Adobe Photoshop and the number of foci were quantified 
using ImageJ’s object counter. Large foci were quantified with ImageJ as well.  
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CHAPTER III 
PSEUDOURIDINE MODIFICATION INHIBITS MUSCLEBLIND-LIKE 1 
(MBNL1) BINDING TO CCUG REPEATS AND SINGLE-STRANDED RNA 
THROUGH REDUCED RNA FLEXIBILITY 
 
 This manuscript has been submitted and reviewed by the Journal of Biological 
Chemistry. I am the primary author on this manuscript. I performed the thermal melt 
assays and the binding experiments. Jeremy Copperman performed the molecular 
dynamics simulations. Dr. J. Andrew Berglund was the primary investigator for this 
work.  
 
INTRODUCTION 
Myotonic dystrophy type 1 (DM1) is a genetic neurodegenerative disease caused 
by an expansion of CTG repeats in the 3’UTR of the dystrophia myotonia protein kinase 
(DMPK) gene. Similar to DM1, myotonic dystrophy type 2 (DM2) is caused by expanded 
CCTG repeats in the zinc finger protein 9 (ZNF9) gene. DM1 and DM2 occur when the 
CTG/CCTG repeats are expanded beyond 40 repeats and patients can have up to 
thousands of CTG/CCTG repeats29,54. The currently accepted DM1 and DM2 disease 
mechanism is that the expanded repeats sequester RNA binding proteins (primarily the 
Muscleblind-like family), which prevents these proteins from performing their functions 
in cells12,37.  
The Muscleblind-like family of proteins (MBNL1, MBNL2 and MBNL3) bind 
RNA and regulate several RNA processing pathways including alternative splicing, pre-
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miRNA biogenesis, mRNA localization and circular RNA generation16,17,100,101. MBNL 
proteins bind the consensus YGCY RNA sequence15,16. CUG and CCUG repeats are 
composed of YGCY motifs creating hundreds or thousands of perfect MBNL binding 
sites resulting in large numbers of MBNL proteins binding the repeats and forming 
nuclear foci18. When MBNL proteins are sequestered they are unable to regulate RNA 
processing events and consequently, many DM1 and DM2 symptoms are caused by mis-
regulated alternative splicing and potentially the loss of other MBNL activities11. It is 
therefore important to understand how MBNL proteins bind their toxic and cellular RNA 
substrates, in order to develop mechanisms to alleviate MBNL sequestration in DM1 and 
DM2.  
MBNL proteins have two sets of Zinc finger domains that are proposed to bind 
RNA on opposing faces of the domain58,59. Teplova et al. published a crystal structure of 
one of MBNL1’s Zinc finger domains in complex with a YGCY-containing RNA, 
showing that MBNL1 interacts with the Watson-Crick face of the GC dinucleotide38. 
This structure indicates that at least this portion of the RNA must be single-stranded in 
order to interact with MBNL1, as the Watson-Crick face interacts with the opposing 
strand in double-stranded RNA.  
Pseudouridine (Ψ) is the most abundant RNA modification, often referred to as 
the fifth RNA base. Ψ is found in tRNA, rRNA and many spliceosomal RNAs and 
functions to stabilize the structure of these RNAs42. Ψ is a 5-ribosyl isomer of uridine, 
with a C-C bond connecting the ribose to the base instead of a C-N bond and an extra H-
bonding donor on the N1 (Fig. 14A). Nuclear magnetic resonance, X-ray crystallography 
and MD simulations have shown that Ψ induces rigidity in both single and double-
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stranded RNA via base-stacking and hydrogen bonding interactions42,46,49. There is 
evidence that in some cases, base-stacking interactions are the primary stabilizing force 
in RNA containing Ψ47. 
Replacing uridines with Ψ in the CUG repeats induced structural stabilization, 
prevented MBNL1 binding and rescued mis-splicing. X-ray crystallography data 
suggested that Ψ stabilized the CUG repeats through water-bridging via hydrogen 
bonding of Ψ’s N1-H with the uridine on the opposing strand 25. In this work we have 
extended our studies to determine that Ψ can stabilize CCUG repeat RNA and single-
stranded RNA containing YGCY motifs and this modification inhibits MBNL1 binding. 
Molecular dynamics simulations indicate that Ψ increases base-stacking interactions in 
single-stranded YGCY RNAs.  
 
RESULTS 
Replacing uridine with Ψ in CCUG repeat RNA increased structural stability 
Previous studies showed that Ψ increased the thermal stability of CUG repeat 
RNA in a helical conformation25. Here we determined if Ψ had a similar effect on 
stabilization of CCUG repeats. The additional cytosine in CCUG repeats renders them 
different from CUG repeats in two ways. First, there is only uridine adjacent to the GC 
dinucleotide, so Ψ substitutions can only change the 5’ side of the YGCY binding site 
unlike the CUG repeats. Second, due to the double cytosine in CCUG repeats, it is 
possible for CCUG repeats to form helices in two different registers. CCUG repeat 
helices in register one have C-U and U-C mismatched base pairs, and adjacent G-C base 
pairs, helices in register two have U-U and C-C mismatches and spaced G-C base pairs 
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(Figure 14B). These RNAs were designed to determine if the different CCUG registers 
have the same degree of structural stability with Ψ modification. Unmodified (CCUG)6 in 
register one melted at 45 ± 2°C, while (CCUG)6 in register one with Ψ substitutions 
melted at 59 ±1°C. Similarly, unmodified (CCUG)6 in register two melted at 46 ± 2°C 
and Ψ substitutions increased the melting temperature to 60 ± 1°C (Figure 14C, 14D and 
Table 6). These data showed that Ψ increased the thermal stability in CCUG repeats and 
the register didn’t appear to make a difference. 
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Figure 14: Pseudouridine (Ψ) increases thermal stability of CCUG repeat 
RNA. (A) representative images of uridine and Ψ. (B) Sequence and predicted 
secondary structures of the two different registers of the (CCUG)6 repeat 
helices used in thermal melt and gel-shift assays.. (C) Thermal melt curves of 
(CCUG)6 in both registers either unmodified or fully pseudouridylated. (D) 
Derivatives of thermal melt curves give the melting temperature of each 
construct. The largest derivative, or the steepest point on the curve, is the 
melting temperature.  	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MBNL has a reduced affinity for CCUG repeats modified with Ψ 
Gel shift assays were used to determine if the Ψ stabilization observed in the 
(CCUG)6 RNAs inhibited MBNL1 binding. The dissociation constant (Kd) for MBNL1 
binding to unmodified (CCUG)6 in register one is 0.16 ± 0.03 µM, modification of 
uridines to Ψ in (CCΨG)6 resulted in an increased Kd of 0.39 ± 0.08 µM. The measured 
dissociation constants for (CCUG)6 and (CCΨG)6 in register two were similar to the 
register one RNAs, with Kds of 0.12 ± 0.03 µM and 0.47 ± 0.09 µM, respectively (Fig 
15A,B and Table 6). These results showed that Ψ had a modest inhibitory effect on 
MBNL1 binding to the YGCY binding sites in the CCUG repeats. This effect is 
significantly less than that observed with Ψ modification of CUG repeats20,25. 
MBNL has reduced affinity for a single-stranded RNA modified with Ψ 
The model MBNL1 RNA substrate [U4(GC)U11(GC)U4] with little RNA structure 
as previously demonstrated59, was used to determine if Ψ modification would inhibit 
MBNL1’s ability to bind ssRNA. The Ψ modification was placed 5’ or 3’ of the GC 
dinucleotide and flanking both GC dinucleotides in the U4(GC)U11(GC)U4 RNA (Figure 
16). The dissociation constant of MBNL1 binding to U4(GC)U11(GC)U4 (unmodified 
RNA) is 0.14 ± 0.09 µM. The addition of a Ψ modification 5’ to the GC increased the Kd 
to 0.83 ± 0.15 µM, while Ψ placement 3’ to the 
GC dinucleotide increased the Kd to 3.2 ± 0.66 
µM, respectively (Fig. 16A,B and Table 7). 
When four pseudouridines flank the two GC 
dinucleotides, the fraction of RNA bound does 
not reach 0.5 in these assays, so we can only 
Table 6: Melthing temperatures and 
MBNL affinities of (CCUG)6 RNAs 
   RNA TM (°C) KD (µM) 
(CCUG)6 R1 45 ± 2 0.16 ± 0.03 
(CCΨG)6 R1 59 ± 1 0.39 ± 0.08 
(CCUG)6 R2 46 ± 2 0.12 ± 0.03 
(CCΨG)6 R2 60 ± 1 0.47 ± 0.09 
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state that the dissociation constant is > 3.2 µM (Figure 16A). Binding curves used to 
calculate these values are shown in Fig. 16B. These results show that MBNL1 was 
generally inhibited by Ψ incorporation; the nucleotide 3’ to the GC dinucleotide had a 
more pronounced affect on MBNL1 binding than the 5’ position as the Kd for the RNA 
with the 3’ Ψ modifications is ~4 fold greater than for the RNA with 5’ modifications 
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Figure 15: MBNL1 has reduced affinity for pseudouridylated (CCUG)6. 
(A) Representative binding gels of MBNL1-(CCUG)6 RNAs with  Ψ 
modification and without modification. MBNL1 concentration increased 
in 2-fold steps from 20 nM to 5 µM. Kd values for RNAs are reported 
below the representative gels. (B) Binding curves for unmodified and Ψ 
modified (CCUG)6 RNAs 
	  
	   	   	  47 
(Figure 16).  
Ψ increases the thermal stability of single-stranded YGCY RNAs 
 Melting studies were performed to determine if the Ψ modifications would 
increase the thermal stability of the MBNL1 model ssRNA substrate. Previous reports 
have shown that Ψ induced base-stacking interactions in single-stranded RNAs predicting 
that increased base-stacking might be observed 49. U4(GC)U11(GC)U4 melted at a  
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Figure 16: MBNL1 has a reduced affinity for single-stranded RNA containing 
pseudouridines. (A) Binding gels of MBNL1-U4(GC)U11(GC)U4 RNAs with increasing 
number of pseudouridines. MBNL1 concentration increased in 2-fold steps from 6.25 nM to 
3.2 µM except for the gel in the upper right panel where MBNL1 concentration ranged from 
9.8 nM to 5 µM. Kd values for RNAs are reported below the representative gels. (B) 
Binding curves for U4(GC)U11(GC)U4 RNA and Ψ modified RNAs. 	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temperature of 29 ± 2°C, which is presumably the un-stacking of the bases in a primarily 
single-stranded structure because there is little possibility of secondary structure with 
only two guanosines in a long string of pryrimidines. The RNA with the two 
pseudouridines 5’ of the GC dinucleotides melted at 42 ± 4°C. The RNA containing 
pseudouridines 3’ to the dinucleotide melted at 40 ± 2°C. The RNA containing Ψ 
substitutions flanking the GC dinucleotides melted at 51 ± 1°C (Figure 17A,B and Table 
7). As shown in figure 17B, melting temperatures are calculated by taking the derivative 
of the melting curve, and the steepest (largest derivative) point is reported. These data 
indicate that Ψ stabilized this single-stranded RNAs by increasing the base stacking in the 
single-stranded RNA. Consistent with this interpretation is that additional Ψ substitutions 
increased the melting temperature (Figure 17B). An increase in thermal stability of these 
ssRNAs is likely due to strand rigidifying via base-stacking interactions. 
Table 7: Melting temperatures and MBNL affinities of 
ssRNA 
   RNA TM (°C) KD (µM) 
U4(GC)U11(GC)U4 29 ± 2 0.14 ± 0.09 
U3Ψ(GC)U10Ψ(GC)U4 42 ± 4 0.83 ± 0.15 
U4(GC)ΨU10(GC)ΨU3 40 ± 2 3.21 ± 0.66 
U3Ψ(GC)ΨU9Ψ(GC)ΨU3 51 ± 1 N/A 
 
Molecular dynamics simulations indicate Ψ increases base-stacking in single-
stranded YGCY RNAs 
We conducted MD simulations to study whether Ψ induces increased base-
stacking interactions in a fully atomistic explicit solvent model single-stranded YGCY 
RNA. MD simulations allowed us to computationally investigate the dynamics of single-
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stranded U5(GC)U5, U4Ψ(GC)U5, U5(GC)ΨU4, and U4Ψ(GC)ΨU4 RNA. There were 
many differences in the conformational ensemble of the native U versus the 
pseudouridylated constructs, overall the pseudouridylated structures were much more 
compact and stable than the ensemble of native U structures.  In order to quantify base-
stacking interactions, we calculated the relative free energy of the distance between the 
U/Ψ5-G and the G-C6 bases throughout the simulation (Figure 18A,B). We define the 
distance between the bases to be the distance between the C2 atom on the G base and the 
C2 (C4) atom on the U (Ψ) base 
  U5-G bases had a global minimum in the stacked configuration but a very small 
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Figure 17: Pseudouridine increases the thermal stability of 
single-stranded YGCY RNAs. (A) Melting curves for 
U4(GC)U11(GC)U4 RNA and modified RNA with Ψ as 
depicted in the legend. Absorbance at 260 nm was measured 
over the temperature range of 10-70°C. (B) Derivatives of 
the thermal melt curves give the melting temperature of 
each construct. 
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barrier of 1.0 kcal/mol separating a range of 
open states of nearly equal free energy to 
the stacked state. Overall the range of open 
conformations, defined as structures with a 
U/Ψ5-G base separation greater than 7 
angstroms were about four times more 
probable than closed conformations (Figure 18B). The widespread distribution of base 
separation distances in the U5GCU5 simulation indicates that the bases are dynamic, 
without a strong preference for base-stacking. Furthermore, analysis of the ensemble of 
open structures of the U5GCU5 from the simulation show that G6 is commonly unstacked 
from both neighboring bases.  
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Figure 18: Molecular dynamics 
simulations indicate Ψ increases base-
stacking in single-stranded YGCY 
RNAs. (A) Free energy of constructs at 
different G-C separation distances in 
U5(GC)U5 modified with Ψ as depicted 
in the legend. Unmodified RNA has 
energy minima at larger G-C separation 
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 While some pseudouridylated constructs displayed slightly increased flexibility at 
small separations, open configurations with a stacking distance to the guanine base of 
greater than 7 angstroms were highly disfavored in comparison to the U5GCU5 construct. 
Pseudouridylation of the 5' U to G6 resulted in increased base-stacking with G6, while 
pseudouridylation of the 3' U7 alone led to increased base-stacking between G6 and C7. 
Pseudouridylation of both U5 and U7 led to increased base stacking on both sides of G6. 
These data suggest that Ψ increases base-stacking interactions in these single-stranded 
YGCY RNAs.  
 
DISCUSSION 
Replacing the uridines in CCUG repeats with pseudouridines increased the 
thermal stability of this RNA in two different registers (Figure 14) by 15°C. Surprisingly, 
this stabilization only resulted in a modest 3- or 4-fold inhibition of MBNL1 binding. 
Stabilization of CUG repeats with Ψ resulted in similar thermal stability (13°C or 19°C 
for two and four Ψ modifications)25 but had a more dramatic effect on MBNL1 binding 
(20-fold and loss of binding)25 compared to CCUG repeat binding. A possible 
explanation for the difference in MBNL1 binding observed between CUG and CCUG 
repeats with Ψ modification is that CCUG repeats are less stable compared to CUG 
repeats and the increased stability provided by the Ψ modification to the CCUG repeats 
wasn’t sufficient to strongly inhibit MBNL1 binding. Another possibility is that 
modifying both pyrimidines of the YGCY motif is necessary for robust inhibition of 
MBNL1 binding.  
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The model ssRNA was used to probe the difference between the two pyrimidine 
positions in the YGCY motif. The modification studies with the ssRNA revealed that the 
Ψ substitution 3’ to the GC dinucleotide had a much more pronounced effect on MBNL1 
binding affinity compared to the 5’ substitution (Figure 16). This difference in binding 
affinity doesn’t appear to be due to thermal stability as the 5’ and 3’ modifications were 
similarly stabilized by Ψ modification (Tms of 40°C, Figure 17 and Table 7). The 
difference in MBNL1 inhibition at the 5’ and 3’ pyrimidine positions may be due to 
contacts made by the Zinc fingers of MBNL1 with the 3’ pyrimidine observed in the 
crystal structure38. The 3’ Ψ modification likely adopts conformations with bases in 
stacked structures that are less compatible with MBNL1 binding. The double Ψ 
modification that nearly eliminated MBNL1 binding (Figure 16) again favors RNA 
conformations with single strand base stacking.  These studies are consistent with the 
crystal structure that showed the zinc fingers of MBNL1 interact primarily with the bases 
in an un-stacked conformation.    
Consistent with the melting studies, molecular dynamics simulations showed that 
Ψ increased the base-stacking interactions in single-stranded YGCY RNAs, particularly 
at the pyrimidine position 5’ to the GC dinucleotide. While the structure published by 
Teplova et al in 2008 shows that the 3’ uridine in the YGCY motif makes contact with 
the protein, this structure also shows that while the RNA is bound to the protein, the G of 
the GC dinucleotide stacks with the protein’s amino acids (Figure 18C). These results 
impose a model in which MBNL1 is able to form interactions with YGCY RNA when it 
is flexible enough for the G to un-stack with its neighboring pyrimidine. At the U-G base 
separation distance of 10.7 angstroms as measured in the crystal structure of bound 
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MBNL1 and RNA, the difference in free energy between the native U and 
pseudouridylated constructs studied in the MD simulations was 1.9 kcal/mol. This is 
significant in a conformational selection model of binding especially when you consider 
this free energy penalty is for a single binding site, while the binding of MBNL1 
U4(GC)U11(GC)U4  interaction involves binding to two of the YGCY sites. The MD 
simulations indicate that Ψ causes the RNA to prefer conformations in which the G is 
stacked with its neighbor. Based on the distribution of base separation distances, 
unmodified RNA also tends to form stacking interactions, but the population of those 
conformations is much less abundant than the range of open configurations. These data 
suggest that Ψ stabilizes YGCY RNA in repeats and single-stranded form likely via a 
combination of base-stacking and hydrogen bonding interactions.  
 
MATERIALS AND METHODS 
Thermal melt assays 
Thermal melts were carried out in 20 mM PIPES buffer at a pH of 7.0 and 150 
mM NaCl. The buffer was de-gassed before diluting RNA to a concentration of 2 μM. 
The temperature was raised by 1°C	 per minute over a range of 10-75°C for ssRNAs and 
15-95°C for CCUG RNAs, and absorbance at 260 nm was monitored by a Cary UV/Vis 
spectrophotometer. Absorbance was normalized by subtracting the absorbance at the 
lowest temperature measured. 
Protein expression and purification 
GST-tagged MBNL1 (amino acids 2-260) was expressed in Arctic Express E. coli 
cells (Agilent TechnologiesTM) grown to an OD of 0.4, induced with 25 mM IPTG and 
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shaken for 20 hours at 16 °C. GST-MBNL1 was initially purified over a Hi-TrapGST 
column on an FPLC. MBNL1 was then cleaved from GST by PreScission Protease and 
purified further by affinity chromatography over a Hi-TrapHeparin column. Both 
columns and the protease were made by GE Healthcare Life SciencesTM. MBNL1 
concentration was measured by a Bradford assay and the protein was stored in a buffer of 
500 mM NaCl, 50% glycerol, 25 mM Tris at pH of 7.5 and 5 mM BME at –80 °C until 
needed.  
Gel-shift binding assays 
RNA synthesized by Dharmacon was radiolabeled with α-32P phosphate with a 
polynucleotide kinase and stored at -20 °C in 20 mM Tris, pH 7.5. Prior to the binding 
reaction, CUG helices were diluted and folded by incubation at 95 °C in 20 mM Tris, pH 
7.5, 150 mM NaCl, and 5 mM MgCl2 for 2 min, followed by incubation on ice for 5 min. 
The RNA was then incubated with varying MBNL1 concentrations in 175 mM NaCl, 20 
mM Tris, pH 7.5, 1 mM BME, 10% glycerol, 5 mM MgCl2, 0.1 mg/mL heparin, 2 
mg/mL BSA, 0.02% xylene cyanol, and 0.05% bromophenol blue. The incubation was 20 
minutes at room temperature. RNA-protein complexes were separated from free RNA on 
a 6% native acrylamide gel. Complex formation was quantified by exposure on a 
phosphorimager screen followed by analysis with ImageQuant from GE Healthcare Life 
SciencesTM. Affinity constants were then calculated with the following equation: fbound = 
fmax([MBNL1]/([MBNL1+Kd)). The images of the gels were enhanced equally across 
each gel using Adobe Photoshop. No specific feature was enhanced. 
 
 
	   	   	  55 
Molecular dynamics simulations 
Atomistic explicit solvent simulations of single-stranded U5(GC)U5 , U5Ψ (GC)U5 
, U5(GC)Ψ U5 , and U5Ψ (GC)Ψ U5  RNA constructs were performed using the 
GROMACS 88-91 molecular dynamics package on the local ACISS cluster at the 
University of Oregon, using an AMBER 92 force-field optimized for stem-loop RNA 
structures with modified force-field parameters for the Ψ base 93.  All simulations were 
performed in explicit solvent utilizing the spc/e water model and 150 mM NaCl with 
excess sodium ions to neutralize the system, Ewald summation for the electrostatics, 
standard force-field cutoffs and parameters. The RNA was initially in an A-form 
structure which was energy minimized after solvation. A 1 fs timestep was utilized in the 
simulation, which was equilibrated over the course of a 5 nanoseconds period. An 
additional 10ns simulation was performed in the production NVT ensemble at 300K, 
from which 10 random snapshots were taken to seed 10 production runs of 10ns each 
from which to collect statistics. 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
MBNL has a decreased affinity for CUG repeats that are structurally stabilized by 
pseudouridine and 2’-O-methyl groups 
 We used structure-stabilizing RNA modifications to address our model of the 
mode of MBNL binding to its targets brought about by the structure published by 
Teplova et al in 2008. While there is abundant evidence that CUG and CCUG repeats 
form helices31-33, this structure shows that MBNL accesses its YGCY binding site 
through interaction with the Watson-Crick face of the GC dinucleotide, which is taken up 
in intra-strand interactions in helices38. Thus, RNA modifications that stabilize helical 
structure should inhibit MBNL binding by preventing it access to its YGCY binding sites 
in CUG and CCUG repeats. As described in chapter II, Ψ and 2’-O-methylation have 
been shown to stabilize RNA secondary structure through various mechanisms46-48.  
To determine whether these modifications have stabilizing effects on CUG 
repeats, we used thermal-melt assays on (CUG)4 RNAs with one, two and four of each 
different modification (Figure 6B). As expected, based on previous structural data 
regarding these modifications42,45, our thermal melt assays showed an elevation of 
melting temperature of the RNAs with modifications, indicating an increase in structural 
stability (Figure 6C). Consistent with the conclusion that these modifications increase 
structural stability, fewer modifications had less of an effect on melting temperature, 
while fully modified RNAs had the most elevated melting temperatures (Figure 6C, 
Table 1)25.  
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After verifying that 2’-O-methylation and pseudouridylation stabilize CUG repeat 
helices, we asked whether this helical stabilization prevents MBNL binding as we 
predicted in our model. We used gel-shift assays to measure MBNL1’s affinity for 
unmodified (CUG)4 and the RNA with one, two and four of each modification. 
Pseudouridylation and 2’-O-methylation decreased MBNL1’s affinity for the described 
(CUG)4 RNAs (Figure 7)25. 2’-O-methylation has a more modest effect on both structural 
stability and MBNL1 affinity than pseudouridylation, indicating that the extent of 
stability corresponds with MBNL1’s affinity, further supporting our model. Because 2’-
O-methylation has only modest effects on CUG repeats structure and MBNL1 affinity, 
we focused primarily on Ψ modifications in subsequent studies.  
MBNL has a decreased affinity for CCUG repeats and single-stranded YGCY RNA 
stabilized by pseudouridine  
 In chapter III, I describe how we continued our studies on how Ψ affects RNA 
structural stability and MBNL association, this time addressing CCUG repeats and 
single-stranded YGCY RNAs. While the bulk of research on myotonic dystrophy 
addresses CUG repeats that are the pathogenic molecule in myotonic dystrophy type 1, it 
is also important to gather information on CCUG repeats, which are pathogenic in 
myotonic dystrophy type 212. Based on the model established by the study in chapter II, 
MBNL proteins interact with YGCY when it is single-stranded. Therefore, we expanded 
our investigation to include Ψ’s affects on single-stranded YGCY RNAs.  
Because Ψ has a stabilizing effect on CUG repeats, we predicted that it would 
also stabilize CCUG repeats25. The extra C in the tetranucleotide CCUG repeat sequence 
inflicts a few important features that make them different from CUG repeats. First, they 
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are capable of forming helices in two different registers (Figure 14B). Register one has 
adjacent G-C base pairs and C-U mismatches. Register two has separated G-C base pairs 
and U-U and C-C mismatches. Secondly, all YGCY motifs in CCUG repeats are flanked 
by a 5’ U and a 3’ C, so Ψ substitution can only be 5’ to the GC dinucleotide 
(CCUGCCUG). We used (CCUG)6 RNA in both registers to determine how Ψ affects its 
thermal stability. As expected, Ψ substitution did increase the thermal stability of CCUG 
repeats (Figure 14C,D, Table 6). Ψ’s effect on CCUG repeat stability was not as robust as 
it was on the thermal stability of CUG repeats documented in chapter II. Following the 
establishment that Ψ stabilizes CCUG repeats in both registers, we measured MBNL1’s 
affinity for pseudouridylated (CCUG)6 in both registers. Here we saw that Ψ reduces 
MBNL1’s affinity for CCUG repeats, as it does for CUG repeats described in chapter II 
(Figure 15 A,B, Table 6). However, MBNL1 has a higher affinity for fully 
pseudouridylated CCUG repeats than it does for fully pseudouridylated CUG repeats. 
This could be because CCUG repeat helices are less stable than CUG repeats, and fully 
pseudouridylated CCUG repeats still have enough single-stranded nature for MBNL1 to 
bind. Alternatively, modifying only the pyrimidine 5’ to the GC dinucleotide might not 
be sufficient to prevent MBNL1 binding.  
We also investigated Ψ’s effects on MBNL1’s ability to bind to single-stranded 
YGCY RNA (U4(GC)U11(GC)U4) and its thermal stability. This RNA is predicted to be 
single-stranded, and was previously shown to be a very good MBNL1 substrate59. 
Replacing the pyrimidines both 5’ and 3’ to each GC dinucleotide severely hampered 
MBNL1 binding. When we measured MBNL1’s affinity for this RNA with Ψ 
substitutions at only the 3’ bases, we also saw a strong decrease in affinity (Figure 16 
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A,B, Table 7). However, when the Ψs are substituted only 5’ to the GC dinucleotide 
MBNL1’s affinity was 4 fold stronger than the former case. This could be due to 
interactions MBNL makes with the 3’ pyrimidine. The structure produced by Teplova et 
al shows that the uridine 3’ to the GC dinucleotide forms hydrogen bonds with MBNL1’s 
zinc finger38. Ψ in this position in place of uridine could alter the conformation of the 
bases such that it is unable to form those hydrogen bonds.  
To determine if MBNL1’s lower affinity for single-stranded RNA with Ψ is due 
to increased thermal stability, we performed thermal melt assays on these RNAs and saw 
that Ψ increased the thermal stability of RNA. In these experiments, however, the 
position of the Ψ does not affect the change in melting temperature. Ψ substitutions 
elevate the melting temperature to the same extent whether 5’ or 3’ to the GC 
dinucleotide. Four substitutions had an even greater effect on the melting temperature of 
this single-stranded RNA (Figure 17 A,B, Table 7). In chapter II we showed how Ψ 
stabilizes secondary structure of CUG repeat helices, but here we see that RNA that 
doesn’t form helices is also stabilized by Ψ and that also blocks MBNL1 binding. This 
implies that not only does MBNL1 prefer to bind to single-stranded RNA, the binding 
site must also be flexible for optimum MBNL1 binding.  
Pseudouridine stabilizes CUG repeats, CCUG repeats and single-stranded YGCY 
RNA through a combination of mechanisms  
In light of the structure-stabilizing capabilities exhibited by Ψ, we were curious as 
to how it stabilizes helical and single-stranded RNA. Ψ has previously been shown to 
stabilize RNA through base-stacking interactions, which would explain how it can induce 
thermal stability of single-stranded RNA49. It is also known to stabilize RNA via 
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hydrogen-bonding interactions by incorporating water bridges between base pairs46. We 
investigated the structure and dynamics of RNAs containing Ψ to address its mechanism 
of stabilization.  
To determine how Ψ affects the structure of CUG repeat helices, we crystallized a 
CUG repeat RNA containing a Ψ substitution (Figure 8A). We used an RNA with four 
CUG repeats attached to a GAAA tetraloop and its receptor to facilitate crystallization, 
which we had previously used to obtain the structure of native CUG repeats33. Initially it 
appeared that the Ψ substitution had very little affect on the helical structure of CUG 
repeats, however further inspection indicated a water molecule bridging the Ψ-U 
mismatch in the crystal structure (Figure 8 B,C, Tables 3,4). Molecular dynamics 
simulations on CUG repeat helices with Ψ substitutions allowed us to investigate water 
coordination and stability of U-U mismatches in a simulated solution. These simulations 
showed that Ψ substitutions in the U-U mismatch induced a higher degree of water 
coordination, which also increased the energy required to break the base pair (Figure 8 D-
F). We determined that the extra hydrogen bonds present in the Ψ-U mismatch with a 
water bridge could account for Ψ’s stabilizing effects.  
 Since Ψ is able to stabilize single-stranded RNA, and single-stranded RNA has 
no base pairs, Ψ must act through an additional stabilizing mechanism. Because Ψ has 
been shown to induce base-stacking interactions, we developed a method of measuring 
base-stacking through molecular dynamics simulations. To do this, we calculated the 
relative free energy of the distance between the G-C and U/Ψ5-G throughout simulations 
on U5GCU5 with 5’ and 3’ Ψ substitutions. Molecules with Ψ substitutions tended to stay 
in a state in which the Ψ stacks with the G, while unmodified molecules adopted many 
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conformations with varying distances between the U and the G. Unmodified YGCY RNA 
was also able to adopt more conformations with larger G-C separation distances than 
RNAs with Ψ  (Figure 18 A,B). These data indicate that Ψ induces base-stacking 
interactions in single-stranded YGCY RNAs. This provides evidence that Ψ stabilizes 
CUG and CCUG repeat helices via a combination of increased base-stacking and water 
molecule coordination.  
CUG repeats modified with pseudouridine lack the ability to abrogate MBNL-
regulated alternative splicing and myotonic dystrophy phenotypes 
 Evidence supporting our model for how MBNL binds CUG repeat helices was 
established in vitro, however I was curious as to whether stabilization of CUG repeat 
helices would affect MBNL’s function in vivo. To address this, I used our established 
splicing assay to determine if MBNL is free to regulate alternative splicing in the 
presence of pseudouridylated repeats. When HeLa cells are transfected with plasmids 
containing long CTG repeats, the cells express long CUG repeats, which form foci and 
sequester MBNL (Figure 10A, upper right panel). We then extract cellular RNA and 
measure exon inclusion levels to determine MBNL’s extent of regulation. In order to test 
whether pseudouridylated CUG repeats affect MBNL-regulated alternative splicing, I in 
vitro transcribed CUG repeats with varying levels of Ψ and transfected them into HeLa 
cells. Unmodified in vitro transcribed CUG repeats disrupted MBNL-regulated 
alternative splicing of its targets TNNT2 and INSR, producing exon inclusion levels 
similar to the CTG plasmid control. Fully pseudouridylated in vitro-transcribed CUG 
repeats did not disrupt alternative splicing of these transcripts, and exon inclusion levels 
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were similar to wild-type (Figure 9). This data provided evidence that the model 
established in vitro functions in vivo as well.  
 Our collaborator Dr. Peter Todd recently developed a myotonic dystrophy model 
zebrafish, which provided us with an opportunity to further test this model in vivo. When 
zebrafish embryos are injected with long CUG repeat RNA, they develop muscle 
function phenotypes and are less viable. Consistent with our observation that 
pseudouridylated CUG repeats do not obstruct MBNL regulated alternative splicing, 
zebrafish embryos injected with pseudouridylated CUG repeats did not develop the 
muscle function phenotype and were as viable as embryos injected with control RNA 
(Figure 11). These results, coupled with the alternative splicing results further establish 
that our model is relevant in vivo. Therefore pseudouridylated CUG repeats would likely 
be less toxic to myotonic dystrophy patients. 
Possible therapeutic approaches to myotonic dystrophy through CUG and CCUG 
repeat structural stabilization 
 Efforts to develop therapeutic molecules to treat myotonic dystrophy patients 
have been approached from different angles. For example, we have identified small 
molecules that reduce levels of CUG repeats in vivo102. Molecules designed to disrupt 
MBNL binding to CUG and CCUG repeats have also been introduced as potential drug 
target molecules35,56,72. Another therapeutic approach that has been investigated is the 
development of antisense oligonucleotides that base pair with CUG repeats and block 
MBNL binding71. The results from my work present another possible therapeutic strategy 
for myotonic dystrophy patients. Introducing Ψ modifications to CUG and CCUG repeats 
in myotonic dystrophy patients would prevent MBNL sequestration and likely relieve 
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disease symptoms. In order to introduce Ψ modifications to CUG and CCUG repeats in 
patient tissues, we would design H/ACA box snoRNAs with target sequences that anneal 
to CUG and CCUG repeats. Once introduced to cells, the snoRNPs containing the 
designer snoRNA and pseudouridine synthase would assemble on the CUG or CCUG 
repeats and convert uridines to Ψ. Advances in delivery systems has made RNA’s use as 
a therapeutic a plausible treatment mechanism, so a snoRNA-based therapeutic is 
conceivable103. 
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